West Virginia University Department of Otolaryngology - Head and Neck Surgery, Morgantown, West Virginia.
Otol Neurotol. 2018 Oct;39(9):1079-1087. doi: 10.1097/MAO.0000000000001957.
Inclusion criteria: 1) treated GJT patients who had no previous treatment with radiosurgery, 2) follow-up with magnetic resonance imaging for at least 12 months, 3) reported pre and posttreatment symptoms, tumor control, or complications for individual PRS patients or for PRS patients as a cohort.
The following were extracted: number of patients, level of evidence, mean age, mean pretreatment tumor volume, tumor control rate, criteria for change in tumor size, symptom control rate, and complications. At the individual patient level the following were extracted: age, number of treatment fractions, total radiation dose to tumor margin, pretreatment tumor volume, Fisch or Glasscock-Jackson stage, pre- and posttreatment symptoms, tumor control, symptom control/improvement, length of follow-up, and complications.
Fifteen studies encompassing 91 patients met criteria. Tumor control was achieved in 92% of patients, symptom control in 93%, and complications occurred in 8%. There was one major complication. Smaller tumor volume predicted improvement in symptoms with PRS.
In the short term, PRS is safe and effective at controlling growth and clinical symptoms for patients with GJTs, though there exists significant selection bias, inconsistent reporting, and clinical heterogeneity among existing studies.
1)通过系统评价和荟萃分析,确定原发性放射外科(PRS)治疗颈静脉球体瘤(GJT)的肿瘤控制、症状控制和并发症发生率。2)确定这些结果的危险因素。
1)从 1950 年 1 月至 2017 年 8 月,在 PubMed、Web of Science、Cochrane 和 EBSCOhost 数据库中搜索英文文章。
纳入标准:1)未经放射外科治疗的 GJT 患者,2)至少有 12 个月的磁共振成像随访,3)单独 PRS 患者或 PRS 患者队列报告治疗前后症状、肿瘤控制或并发症。
提取了以下信息:患者人数、证据水平、平均年龄、平均术前肿瘤体积、肿瘤控制率、肿瘤大小变化标准、症状控制率和并发症。在个体患者水平上,提取了以下信息:年龄、治疗次数、肿瘤边缘总放射剂量、术前肿瘤体积、Fisch 或 Glasscock-Jackson 分期、治疗前后症状、肿瘤控制、症状控制/改善、随访时间和并发症。
15 项研究共纳入 91 例患者符合标准。92%的患者肿瘤得到控制,93%的患者症状得到控制,8%的患者发生并发症。有 1 例严重并发症。PRS 可使肿瘤体积缩小,从而改善症状。
在短期内,PRS 治疗 GJT 安全有效,可控制肿瘤生长和临床症状,但现有研究存在明显的选择偏倚、报告不一致和临床异质性。